The incidence of urinary retention‐related AEs was significantly higher among male patients, patients ≥ 65 years old, patients with a prostate volume ≥ 50 mL, patients with lower urinary tract obstruction disease or BPH as comorbidity, or patients using α1 blockers or PDE5 inhibitors as concomitant medications (p < 0.05). Here, PDE5A is linked to benign prostatic hyperplasia.